ImpediMed Limited - Business-News-Today.com

Business-News-Today.com

Business news, market intelligence, and global industry analysis.

Business-News-Today.com

The Latest

Willow Lane Acquisition enters public markets with $10 per unit IPO, betting on selective dealmaking

Galaxy Surfactants (NSE: GALAXYSURF) Q3 FY26 results signal portfolio resilience as specialty growth offsets global surfactant pressures

Natural Capsules (NSE: NATCAPSUQ) Q3 FY26 results signal operational recovery after regulatory shock, but fermentation execution risk still looms

Why Eli Lilly and Company is stockpiling a weight loss pill before the FDA has even said yes

Visual comparison of top ASX-listed medtech companies in 2025—Cardiex, ResMed, ImpediMed, and Volpara—highlighting their innovation focus, AI integration, and stock momentum.

Read More

4 minute read

Healthcare Industry News

How Cardiex, ResMed, ImpediMed, and Volpara are shaping Australia’s MedTech future in 2025

Comparing Cardiex, ResMed, ImpediMed, and Volpara in 2025 to see which ASX medtech firm is best positioned for growth in diagnostics, AI, and digital health.

byPallavi Madhiraju

June 2, 2025

web analytics